Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adolescent Oncology Patients Clear all
Completed No phase listed Observational

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

NCT01793233
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma, Lymphoma
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
97
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Improving Health Insurance Experiences for Adolescent and Young Adult Cancer Patients

NCT04448678
View directory record Official record
Conditions
Adolescent, Young Adult, Cancer
Interventions
Health Insurance Education Program (HIEP), Usual Care
Behavioral · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 40 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

NCT04167618
View directory record Official record
Conditions
Medulloblastoma, Childhood
Interventions
177Lu-DTPA-omburtamab
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
3 Years to 19 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Rochester, Minnesota • New York, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

NCT00560144
View directory record Official record
Conditions
Neoplasms
Interventions
RG1507
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Not applicable Interventional

Development and Evaluation of a Screening Approach for Sexual Dysfunction in AYA Patients With and Surviving Childhood Cancer

NCT05524610
View directory record Official record
Conditions
Pediatric Cancer, Survivorship
Interventions
Sexual Function Screening Approach
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years to 24 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Phase 3 Interventional

Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

NCT05443737
View directory record Official record
Conditions
Cancer, Fertility Preservation
Interventions
Multi-component oncofertility care intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
0 Years to 50 Years
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • El Centro, California • La Jolla, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

NCT02596503
View directory record Official record
Conditions
Relapsed Solid Tumors, Refractory Solid Tumors
Interventions
Eribulin, Irinotecan, Cefixime
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Lexington, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

NCT04770246
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
Interventions
TAS-117
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Santa Monica, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

NCT04225676
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

NCT02433483
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Cytarabine, Intrathecal Triples, HPC-A
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Not applicable Interventional

Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients

NCT07359911
View directory record Official record
Conditions
Sarcoma
Interventions
Exercise Intervention, Usual Care Control, Exit Interview
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
12 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

NCT02684058
View directory record Official record
Conditions
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
Interventions
Dabrafenib, trametinib, Carboplatin, Vincristine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

NCT02304458
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Not applicable Interventional

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention

NCT06982066
View directory record Official record
Conditions
Pediatric Cancer, Adolescent and Young Adult Cancer
Interventions
ReSPECT
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
15 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional

Talking Pictures Social Media Intervention in Reducing Depressive Symptoms and Improving Spiritual Well-Being and Quality of Life in Adolescent and Young Adult Cancer Patients

NCT03679585
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
15 Years to 34 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

NCT00302003
View directory record Official record
Conditions
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
Interventions
radiation therapy, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, ifosfamide, vinorelbine tartrate, dexamethasone, etoposide phosphate, cisplatin, cytarabine, filgrastim
Radiation · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional

Remote Ischemic Conditioning in Oncology

NCT04805346
View directory record Official record
Conditions
Participants Undergoing Anthracycline Chemotherapy
Interventions
autoRIC®
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting No phase listed Observational

A Study of Questionnaires in Adolescents and Young Adults With Cancer

NCT07212166
View directory record Official record
Conditions
Adolescents and Young Adults With Cancer
Interventions
Patient-Reported Outcome Surveys, Spanish version of PRO-AYA and the cognitive interview
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

NCT05464836
View directory record Official record
Conditions
Leukemia, Lymphoblastic, Leukemia
Interventions
CB-103, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT01141244
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
temsirolimus, temozolomide, irinotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

PREVENT HPV -Related Cancers Trial

NCT07217145
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Durvalumab in Pediatric and Adolescent Patients

NCT02793466
View directory record Official record
Conditions
Solid Tumor, Lymphoma, Central Nervous System Tumors
Interventions
Durvalumab; MEDI4736
Drug
Lead sponsor
Leo Mascarenhas
Other
Eligibility
1 Year to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Completed No phase listed Observational Results available

Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer

NCT01618344
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 29 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

NCT00003955
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 6:24 AM EDT